北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer
作者: Fang, Hong; Lin, Rong-Yan; Sun, Ming-Xia; Wang, Qian; Zhao, Yu-Liang; Yu, Jing-Lin; Tian, Yan; Wang, Xiao-Yun
关键词: NSCLC ; gefitinib ; cisplatin ; gemcitabine ; adenocarcinoma ; survival ; associated influencing factors
刊名: ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
发表日期: 2014
DOI: 10.7314/APJCP.2014.15.24.10967
卷: 15, 期:24, 页:10967-10970
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: PHASE-III ; CHEMOTHERAPY
英文摘要:

Objective: To analyze the efficacy and survival associated factors of gefitinib combined with cisplatin and gemcitabine for advanced non-small cell lung cancer. Materials and Methods: A total of 57 patients with advanced non-small cell lung cancer (NSCLC), who received platinum-based chemotherapy regimens for more than 1 cycle, were treated with gefitinib combined with cisplatin and gemcitabine until disease progression. Efficacy, survival time and adverse reactions were observed. The Kaplan-Meier method was adopted for analysis of survival and Cox regression for associated influencing factors. Results: The patients were followed up until October 31, 2013, and the median follow-up time was 19 months. Of 57 patients, there were 4 (7.0%) with complete remission (CR), 8 (14.0%) with partial remission, 31 (54.4%) with stable disease, and 14 (24.6%) with disease progression. The remission rate was 21.1% and the disease control rate was 75.4%. The median progression-free survival (PFS) time and the median overall survival time were 10 months and 15.2 months. The one-year, two-year and three-year survival rates were 47.4%, 23.3% and 10.0%. Gender and pathological types were the independent risk factors influencing PFS time (P=0.028, P=0.009). Tumor pathological type and early efficacy were independent factors for the prognosis (P=0.018, P=0.000). Adverse reactions were mostly rashes of I similar to II degree and diarrhea and slightly increasing level of aminopherase. The skin adverse event incidence of. degree or above was 1.8% (1/57) and brain metastasis was foudn in 31.6% (18/57). Conclusions: Gefitinib combined with cisplatin andgemcitabine, is effective for patients with IIIb similar to IV NSCLC who received multiple cycles of chemotherapy.

语种: 英语
WOS记录号: WOS:000351058900072
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65811
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Dept Oncol Chemotherapy, Hosp 1, Beijing 100871, Peoples R China

Recommended Citation:
Fang, Hong,Lin, Rong-Yan,Sun, Ming-Xia,et al. Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer[J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION,2014,15(24):10967-10970.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Fang, Hong]'s Articles
[Lin, Rong-Yan]'s Articles
[Sun, Ming-Xia]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Fang, Hong]‘s Articles
[Lin, Rong-Yan]‘s Articles
[Sun, Ming-Xia]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace